Search J Rheum

Advanced Search

Home

Current Issue

Archives

Guidelines for Authors

Classified Ads

Links

Subscriptions

Subscriber Registration

Guidelines for Website Users

JRheum Update Service

Contact Info

Accelerated Alveolar Bone Loss in HLA-B27 Transgenic Rats: An Adult Onset Condition

DIMITRIS N. TATAKIS, PAOLA GUGLIELMONI, and HANSEL M. FLETCHER

ABSTRACT.

Objective.
Patients with arthritis and Crohn's disease may be more susceptible to periodontitis associated alveolar bone loss (ABL). HLA-B27 transgenic (TG) rats spontaneously develop arthritis and colitis. Based on the hypothesis that TG rats would also be susceptible to ABL, we compared the naturally occurring ABL in TG and Fischer 344 wild-type (WT) rats.

Methods. Eighteen TG and 18 WT virgin female rats were used. Pairs (1 TG, 1 WT) were housed in suspended wire cages. At age 2.6, 6, and 11 months, 8, 5, and 5 pairs were sacrificed, respectively. ABL was measured as exposed molar root surface area (mm2). Western blotting was used for analysis of serum reactivity against bacteria associated with arthritis, colitis, and periodontitis development.

Results. At 2.6 months of age, there was no difference in ABL between TG and WT rats. At 6 and 11 months ABL was significantly greater in TG animals by 28% and 53%, respectively. For TG rats, ABL was significantly different between the 3 age groups. For WT rats, ABL was not significantly different between 6 and 11 months. Western blotting revealed distinct TG serum reactivity against extracts of Bacteroides vulgatus, B. fragilis, Prevotella intermedia, and to a lesser extent against extracts of B. forsythus.

Conclusion. The accelerated ABL in HLA-B27 TG rats is an adult onset condition, independent of husbandry conditions or parity status. HLA-B27 rats exhibit strong immunoreactivity against bacteria implicated in arthritis, colitis, and periodontitis. (J Rheumatol 2002;29:1244-51)

Key Indexing Terms:

ALVEOLAR BONE LOSS
DISEASE MODELS
IMMUNOLOGY
HLA-B27
RATS
ANTIBODIES


From the Department of Periodontics, School of Dentistry, and Department of Microbiology and Molecular Genetics, School of Medicine, Loma Linda University, Loma Linda, California, USA.

Supported by GenPharm International and the Loma Linda University Schools of Dentistry, grant 0313-4005 (DNT), and Medicine, grant 0316-6837 (HMF).

D.N. Tatakis, DDS, PhD, Department of Periodontics, School of Dentistry, Loma Linda University, currently: Section of Periodontology, College of Dentistry, Ohio State University, Columbus, OH; P. Guglielmoni, DDS, MS, Department of Periodontics, School of Dentistry, Loma Linda University, currently: Department of Stomatology, School of Dentistry, University of California at San Francisco, and private practice, San Francisco, CA; H.M. Fletcher, PhD, Department of Microbiology and Molecular Genetics, School of Medicine, Loma Linda University.

Address reprint requests to Dr. D.N. Tatakis, Section of Periodontology, College of Dentistry, The Ohio State University, 305 West 12th Avenue, PO Box 182357, Columbus, OH 43218-2357. E-mail: tatakis.1@osu.edu

Submitted June 29, 2001; revision accepted December 21, 2001.




Return to June 2002 Table of Contents



© 2002. The Journal of Rheumatology Publishing Company Limited.
All rights reserved.